Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/7608
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAl-Hatamleh, Mohammad A.I.-
dc.contributor.authorAbusalah, Mai A.-
dc.contributor.authorHatmal, Ma’mon M.-
dc.contributor.authordkk.-
dc.date.accessioned2024-11-09T02:52:53Z-
dc.date.available2024-11-09T02:52:53Z-
dc.date.issued2023-
dc.identifier.issn1658-3612-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/7608-
dc.description.abstractUnlike pandemics in the past, the outbreak of coronavirus disease 2019 (COVID-19), which rapidly spread worldwide, was met with a different approach to control and measures implemented across affected countries. The lack of understanding of the fundamental nature of the outbreak continues to make COVID-19 challenging to manage for both healthcare practitioners and the scientific community. Challenges to vaccine development and evaluation, current therapeutic options, convalescent plasma therapy, herd immunity, and the emergence of reinfection and new variants remain the major obstacles to combating COVID-19. This review discusses these challenges in the management of COVID-19 at length and highlights the mechanisms needed to provide better understanding of this pandemic.en_US
dc.language.isoen_USen_US
dc.publisherJournal of Taibah University Medical Sciencesen_US
dc.relation.ispartofseriesReview Article;600-638-
dc.subject2019-nCoVen_US
dc.subjectConvalescent plasma therapyen_US
dc.subjectCoronavirusen_US
dc.subjectHerd immunityen_US
dc.subjectReinfectionen_US
dc.subjectSARS-CoV-2en_US
dc.titleUnderstanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfectionen_US
dc.typeArticleen_US
Appears in Collections:Vol 18 No 3 (2023)

Files in This Item:
File Description SizeFormat 
600-638.pdf600-6389.46 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.